Report from the Radiation Oncology Committee of the Southwest Oncology Group (SWOG): Research objectives workshop 2003

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 26, Issue 5, 2003, Pages 522-529

  Okunieff, Paul ^a   Meyn, Raymond E ^b   Teicher, Beverly A ^c   Thomas Jr , Charles R ^d   Gaspar, Laurie E ^e   Raben, David ^e   Giri, Shankar ^f   Lavey, Robert S ^g   Turrisi III, Andrew T ^h   Swanson, Gregory P ⁱ   Smalley, Stephen R ^j  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c GENZYME CORPORATION   (United States)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^e UNIVERSITY OF COLORADO   (United States)

^f EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^g UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^h MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

ⁱ Deaconess Medical Center Spokane   (United States)

^j Olathe Regional Oncology Center   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; CANCER CONTROL; CANCER RADIOTHERAPY; COLON CANCER; CONFERENCE PAPER; DIAGNOSTIC IMAGING; METASTASIS; PROSTATE CANCER; SARCOMA; SURVIVAL RATE;

ANTINEOPLASTIC AGENTS; BIOLOGICAL RESPONSE MODIFIERS; COMBINED MODALITY THERAPY; HUMANS; NEOPLASMS; RADIATION ONCOLOGY; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY DOSAGE;

EID: 10744229935     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.coc.0000092253.71406.2b     Document Type: Conference Paper

References (82)

1. Teicher BA, Holden SA, Al-Achi A, et al. Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FSaIIC murine fibrosarcoma. Cancer Res. 1990;50:3339-3344.
2. Herman TS, Teicher BA, Pfeffer MR, et al. Effect of acidic pH on radiosensitization of FSaIIC cells in vitro by misonidazole, etanidazole, or cis-diamminedichloroplatinum (II). Radiat Res. 1990;124:28-33.
3. Guchelaar HJ, Hoekstra HJ, de Vries EG, et al. Cisplatin and platinum pharmacokinetics during hyperthermic isolated limb perfusion for human tumours of the extremities. Br J Cancer. 1992;65:898-902.
4. Vaden SL, Page RL, Williams PL, et al. Effect of hyperthermia on cisplatin and carboplatin disposition in the isolated, perfused tumour and skin flap. Int J Hypertherm. 1994;10:563-572.
5. Li TS, Kaneda Y, Saeki K, et al. Pharmacokinetic differences between rat tumour and lung tissues following isolated lung perfusion with cisplatin. Eur J Cancer. 1999;35:1846-1850.
6. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res. 1989;49:6449-6465.
7. Thomas CR Jr, Giroux DJ, Stelzer KJ, et al. Concurrent cisplatin, prolonged oral etoposide, and vincristine plus chest and brain irradiation for limited small cell lung cancer: a phase II study of the Southwest Oncology Group (SWOG-9229). Int J Radiat Oncol Biol Phys. 1998; 40:1039-1047.
8. Green JA, Kirwan JM, Tierney JF, et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet. 2001;358:781-786.
9. Onishi H, Yamaguchi M, Kuriyama K, et al. Effect of concurrent intra-arterial infusion of platinum drugs for patients with stage III or IV uterine cervical cancer treated with radical radiation therapy. Cancer J Sci Am. 2000;6:40-45.
10. He Q, Skog S, Welander I, et al. X-irradiation effects on thymidine kinase (TK): I. TK1 and 2 in normal malignant cells. Cell Proliferat. 2002;35:69-81.
11. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725-730.
12. Schilsky RL. Pharmacology and clinical status of capecitabine. Oncol (Huntington). 2000;14:1297-1306.
13. Schuller J, Cassidy J, Dumont E, et al. Preferential activation of capecitabine in tumor following oral administration to colorectal patients. Cancer Chemother Pharmacol. 2000;45:291-297.
14. Sawada N, Ishikawa T, Sekiguchi F, et al. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin Cancer Res. 1999;5:2948-2953.
15. Vaishampayan UN, Ben-Josef E, Philip PA, et al. A single institution experience with concurrent capecitabine and radiation therapy in gastrointestinal malignancies. Int J Radiat Oncol Biol Phys. 2002;53:675-679.
16. Ortmann E, Hohenberg G. Treatment side effects. Case 1. Radiation recall phenomenon after administration of capecitabine. J Clin Oncol. 2002;20:3029-3030.
17. Rich T. Capecitabine and radiation therapy for advanced gastrointestinal malignancies. Oncol (Huntington). 2002;16(12 suppl 14):27-30.
18. McGinn CJ, Shewach DS, Lawrence TS. Radiosensitizing nucleosides. J Natl Cancer Inst. 1996;88:1193-1203.
19. Lawrence TS, Chang EY, Hahn TM, et al. Radiosensitization of pancreatic cancer cells by 2′, 2′-difluoro-2′-deoxycytidine. Int J Radiat Oncol Biol Phys. 1996;34:867-872.
20. Urtasun RC, Cosmatos D, DelRowe J, et al. Iododeoxyuridine (IUdR) in combination with radiation in the treatment of malignant glioma: a comparison of short versus long intravenous dose schedules (RTOG 86-12). Int J Radiat Oncol Biol Phys. 1993;27:207-214.
21. Urtasun RC, Kinsella TJ, Faman N, et al. Survival improvement in anaplastic astrocytoma, combining external radiation with halogenated pyrimidines: final report of RTOG 86-12, Phase I-II Study. Int J Radiat Oncol Biol Phys. 1996;36:1163-1167.
22. Phillips TL, Scott CB, Leibel SA, et al. Results of a randomized comparison of radiotherapy and bromodeoxyuridine with radiotherapy alone for brain metastases: report of RTOG Trial 89-05. Int J Radiat Oncol Biol Phys. 1995;33:339-348.
23. Sullivan FJ, Herscher LL, Cook JA, et al. National Cancer Institute (phase II) study of high-grade glioma treated with accelerated hyperfractionated radiation and iododeoxyuridine: results in anaplastic astrocytoma. Int J Radiat Oncol Biol Phys. 1994;30:583-590.
24. Cividalli A, Lividi E, Ceciarelli F, et al. Combined use of gemcitabine and radiation in mice. Anticancer Res. 2001;21:307-312.
25. Crane C, Wolff R, Abbruzzese J, et al. Combining gemcitabine with radiation in pancreatic cancer: understanding important variables influencing the therapeutic index. Semin Oncol. 2001;28(3 Suppl 10):25-33.
26. Classen J, Paulsen F, Hehr T, et al. Effect of gemcitabine on acute and late radiation toxicity of skin and underlying soft tissues to single-dose irradiation in a nude mice model. Int J Radiat Oncol Biol Phys. 2002;53:197-205.
27. McGinn CJ, Lawrence TS, Zalupski MM. On the development of gemcitabine-based chemotherapy regimens in pancreatic cancer. Cancer. 2002;95(suppl 4):933-940.
28. Chen AY, Okunieff P, Pommier Y, et al. Mammalian DNA topoisomerase I mediates the enhancement of radiation cytotoxicity by camptothecin derivatives. Cancer Res. 1997;57:1529-1536.
29. Teicher BA, Holden SA, Khandakar V, et al. Addition of a topoisomerase I inhibitor to trimodality therapy [cis-diamminedichloroplatinum(II)/heat/radiation] in a murine tumor. J Cancer Res Clin Oncol. 1993;119:645-651.
30. Kohara H, Tabata M, Kiura K, et al. Synergistic effects of topoisomerase I inhibitor, 7-ethyl-10-hydroxycamptothecin, and irradiation in a cisplatin-resistant human small cell lung cancer cell line. Clin Cancer Res. 2002;8:287-292.
31. Kim JS, Amorino GP, Pvo H, et al. Radiation enhancement by the combined use of topoisomerase 1 inhibitors, RFS-2000 or CPT-11, and topoisomerase II inhibitor etoposide in human lung cancer cells. Radiother Oncol. 2002;62:61-67.
32. Pisters PW, Ballo MT, Patel SR. Preoperative chemoradiation treatment strategies for localized sarcoma. Ann Surg Oncol. 2002;9:535-542.
33. Choy H, Rodriguez F, Koesterm F, et al. Investigation of Taxol as a potential radiation sensitizer. Cancer. 1993;71:3774-3778.
34. Liebmann J, Cook JA, Fisher J, et al. Changes in radiation survival curve parameter in human tumor and rodent cells exposed to paclitaxel (Taxol). Int J Radiat Oncol Biol Phys. 1994;29:559-564.
35. Keng PC, Okunieff P, Chen Y. Low dose Taxol/Taxotere radiosensitization for human lung cancer cells is schedule dependent. Int J Radiat Oncol Biol Phys. 2000;48(3 Suppl 1):272-273.
36. Milross CG, Mason KA, Hunter NR, et al. Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel. J Natl Cancer Inst. 1996;88:1308-1314.
37. Chen Y, Pandya, K, Raubertas R, et al. Low dose pulsed paclitaxel and concurrent radiation for thoracic malignancies: a phase I/II clinical trial based on cell cycle studies of human lung cancer cells. Int J Radiat Oncol Biol Phys. 2000;48(3 suppl 1):326-327.
38. Langer C, Paulus R, Ruffer J, et al. Phase II RTOG trial of weekly Paclitaxel (TAX) and conventional external beam radiation therapy (ebrt) for supratentorial glioblastoma multiforme (GBM). J Clin Oncol. 1999;534:139a.
39. Ruffer J, Scott C, Langer C, et al. A phase II trial of weekly paclitaxel and conventional radiotherapy for supratentorial glioblastoma multiforme: RTOG 96-02. Int J Radiat Oncol Biol Phys. 1998;42:265.
40. Araki S, Miyagi Y, Kawanishi K, et al. Neoadjuvant treatment with docetaxel and the effects of irradiation for human ovarian adenocarcinoma and cervical squamous cell carcinoma in vitro. Acta Medica Okavama. 2002;56:13-18.
41. Caffo O. Radiosensitization with chemotherapeutic agents. Lung Cancer. 2001;3:S81-S90.
42. vanBree C, Castro Kreder N, Loves WJ, et al. Sensitivity to ionizing radiation and chemotherapeutic agents in gemcitabine-resistant human tumor cell lines. Int J Radiat Oncol Biol Phys. 2002;54:237-244.
43. Hanna YM, Baglan KL, Stromberg JS, et al. Acute and subacute toxicity associated with concurrent adjuvant radiation therapy and paclitaxel in primary breast cancer therapy. Breast J. 2002;8:149-153.
44. Adelstein DJ, Rice TW, Rybicki LA, et al. Accelerated hyperfractionated radiation concurrent paclitaxel/cisplatin chemotherapy and surgery for stage III non-small cell lung cancer. Lung Cancer. 2002;36:167-174.
45. 90yttrium-DOTA-peptide-ChL6. Prostate. 2002;50:27-37.
46. Pluquet O, Hainaut P. Genotoxic and non-genotoxic pathways of p53 induction. Cancer Lett. 2001;174:1-15.
47. Mouta Carreira C, Landriscina M, Bellum S, et al. The comparative release of FGF1 by hypoxia and temperature stress. Growth Factors. 2001;18:277-2135.
48. Semenza GL. Involvement of hypoxia-inducible factor 1 in human cancer. Intern Med. 2002;41:79-83.
49. Brizel DM, Scully SP, Harrelson JM, et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res. 1996;56:941-943.
50. Vaupel P, Kelleher DK, Höckel M. Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. Semin Oncol. 2001;28:29-35.
51. Vaupel P, Thews O, Höckel M. Treatment resistance of solid tumors: role of hypoxia and anemia. Med Oncol. 2001;18:243-259.
52. el-Said A, Menke D, Dorie MJ, et al. Comparison of the effectiveness of tirapazamine and carbogen with nicotinamide in enhancing the response of a human tumor xenograft to fractionated irradiation. Radiat Oncol Invest. 1999;7:163-169.
53. Le Q, Chansky K, Williamson SK, et al. SWOG 0004 - pilot study of tirapazamine (TPZ) plus cisplatin/etoposide (PE) and concurrent thoracic radiotherapy (RT) in limited small cell lung cancer (LSCLC). Proc ASCO. 2002;11741.
54. Saunders MI, Hoskin PJ, Pigott K, et al. Accelerated radiotherapy, carbogen and nicotinamide (ARCON) in locally advanced head and neck cancer: a feasibility study. Radiother Oncol. 1997;45:159-166.
55. Kaanders JH, Bussink J, van der Kogel AJ. ARCON: a novel biology-based approach in radiotherapy. Lancet Oncol. 2002;3:728-737.
56. 2 concentrations. Adv Exp Med Biol. 1997;428:79-87.
57. Huang SM, Li J, Armstrong EA, et al. Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa). Cancer Res. 2002;62:4300-4306.
58. Keyes K, Cox K, Treadway P, et al. An in vitro tumor model: analysis of angiogenic factor expression after chemotherapy. Cancer Res. 2002; 62:5597-5602.
59. 2) transgene. Radiat Res. 2002;159:361-370.
60. Rasmussen H, Rasmussen C, Lempicki M, et al. TNFerade Biologic: preclinical toxicology of a novel adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha. Cancer Gene Ther. 2002;9:951-957.
61. Vose JM, Link BK, Grossbard ML, et al. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2001;19:389-397.
62. Hainsworth JD, Litchy S, Barton JH, et al. Minnie Pearl Cancer Research Network. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol. 2003;21:1746-1751.
63. Rubin P, Johnston CJ, Williams JP, et al. A perpetual cascade of cytokines postirradiation leads to pulmonary fibrosis. Int J Radiat Oncol Biol Phys. 1995;33:99-109.
64. Chen Y, Rubin P, Williams J, et al. Circulating IL-6 as a predictor of radiation pneumonitis. Int J Radiat Oncol Biol Phys. 2001;49:641-648.
65. Anscher MS, Peters WP, Reisenbichler H, et al. Transforming growth factor-β as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer. N Engl J Med. 1993;328:1592-1598.
66. Marshall JM. The integrated response to hypoxia: from circulation to cells. Exp Physiol. 1999;84:449-470.
67. Brizel D, Schroeder T, Scher RL, et al. Elevated tumor lactate concentrations predict for an increased risk of metastases in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2001;51:349-353.
68. Höckel M, Vaupel P. Biological consequences of tumor hypoxia. Semin Oncol. 28(suppl):36-41, 2001.
69. Milas L. Cyclooxygenase-2 (COX-2), enzyme inhibitors as potential enhancers of tumor radioresponse. Semin Radiat Oncol. 2001;11:290-299.
70. Epperly MW, Defilippi S, Sikora C, et al. Radio-protection of lung and esophagus by overexpression of the human manganese superoxide dismutase transgene. Mil Med. 2002;167(2 Suppl):71-73.
71. Okunieff P. Interactions between ascorbic acid and the radiation of bone marrow, skin, and of tumor. Am J Clin Nutr. 1991;54(6 suppl): 12815-12835.
72. Vijayalaxmi TCR Jr., Reiter RJ, Herman TS. Melatonin: from basic research to cancer treatment clinics. J Clin Oncol. 2002;20:2575-2601.
73. Futran ND, Trotti A, Gwede C. Pentoxifylline in the treatment of radiation-related soft tissue injury: preliminary observations. Laryngoscope. 1997;107:391-395.
74. Pateder DB, Sheu TJ, O'Keefe RJ, et al. Role of pentoxifylline in preventing radiation damage to epiphyseal growth plate chondrocytes. Radiat Res. 2002;157:62-68.
75. Okunieff P, Li M, Liu W, et al. Keratinocyte growth factors radioprotect bowel and bone marrow but not KHT sarcoma. Am J Clin Oncol. 2001;24:491-495.
76. Ader I, Muller C, Bonnet J, et al. The radioprotective effect of the 24 kDa FGF-2 isoform in HeLa cells is related to an increased expression and activity of the DNA dependent protein kinase (DNA-PK) catalytic subunit. Oncogene. 2002;21:6471-6479.
77. Kolb M, Bonniaud P, Galt T, et al. Differences in fibrogenic response after transfer of active transforming growth factor-beta 1 gene to lungs of "fibrosis-prone" and "fibrosis-resistant" mouse strains. Am J Respir Cell Mol Biol. 2002;27:141-150.
78. Chen Y, Williams J, Ding I, et al. Radiation pneumonitis and early circulatory markers. Semin Radiat Oncol. 2002;12(suppl):26-33.
79. Stone HB, McBride WH, Coleman CN. Modifying normal tissue damage postirradiation. Report of a workshop sponsored by the Radiation Research Program, National Cancer Institute, Bethesda, Maryland, September 6-8, 2000. Radiat Res. 2002;157:204-223.
80. Motamed M, Banerjee AR, Bradley PJ, et al. MIB-1 and p53 expression in radiotherapy-resistant T1aN0M0 glottic squamous cell carcinoma. Clin Otolaryngol All Sci. 2001;26:227-230.
81. Alkushi A, Irving J, Hsu F, et al. Immunoprofile of cervical and endometrial adenocarcinomas using tissue microarray. Virchows Archiv. 2003;442:271-277.
82. Haston CK, Wang M, Dejoumett RE, et al. Bleomycin hydrolase and a genetic locus within the MHC affect risk for pulmonary fibrosis. Human Mol Gen. 2002;11:1855-1863.